| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/13543784.2011.548803 |
| P953 | full work available at URL | http://www.informapharmascience.com/doi/abs/10.1517/13543784.2011.548803 |
| http://www.tandfonline.com/doi/pdf/10.1517/13543784.2011.548803 | ||
| P698 | PubMed publication ID | 21235429 |
| P2093 | author name string | Jeffrey N. Miner | |
| Mark S. Chapman | |||
| P2860 | cites work | EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib | Q24561953 |
| RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer | Q27657185 | ||
| RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth | Q27659493 | ||
| MEK1 mutations confer resistance to MEK and B-RAF inhibition | Q27777362 | ||
| Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers | Q27851426 | ||
| BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation | Q27851610 | ||
| Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors | Q28297412 | ||
| Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo | Q28368373 | ||
| Cancer statistics, 2009 | Q29547625 | ||
| BRAF mutation predicts sensitivity to MEK inhibition | Q29614281 | ||
| Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase | Q29616448 | ||
| Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer | Q29618155 | ||
| Ordered phosphorylation of p42mapk by MAP kinase kinase | Q30438677 | ||
| Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts | Q33709656 | ||
| The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. | Q34014364 | ||
| A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer | Q34106382 | ||
| Dysregulation of Met receptor tyrosine kinase activity in invasive tumors | Q34584046 | ||
| MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors | Q35794067 | ||
| Targeting the mitogen-activated protein kinase cascade to treat cancer | Q35968411 | ||
| Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling | Q36288956 | ||
| Sorafenib: delivering a targeted drug to the right targets | Q36817095 | ||
| Recent advances of MEK inhibitors and their clinical progress | Q36907524 | ||
| BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications | Q36972859 | ||
| Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma | Q36980836 | ||
| Ras and phosphoinositide 3-kinase: partners in development and tumorigenesis | Q36997611 | ||
| MAPKs and their relevance to arthritis and inflammation | Q37054686 | ||
| Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. | Q37109225 | ||
| Oncogene addiction | Q37152445 | ||
| Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition | Q37331610 | ||
| Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway. | Q37370630 | ||
| Targeting the RAF-MEK-ERK pathway in cancer therapy | Q37393116 | ||
| Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases | Q37421620 | ||
| Small molecules and targeted therapies in distant metastatic disease. | Q37555793 | ||
| Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer | Q38445646 | ||
| Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models | Q39706127 | ||
| E6201 [(3S,4R,5Z,8S,9S,11E)-14-(ethylamino)-8, 9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione], a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (M | Q39812078 | ||
| In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. | Q39830937 | ||
| Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells | Q39877518 | ||
| AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl | Q40093939 | ||
| Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein | Q40109392 | ||
| Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor | Q40164535 | ||
| MEK1 and MEK2, different regulators of the G1/S transition. | Q40530177 | ||
| Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies | Q42521987 | ||
| PIKing the right patient | Q43031144 | ||
| Selective role for Mek1 but not Mek2 in the induction of epidermal neoplasia. | Q43244288 | ||
| A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal | Q43543397 | ||
| Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies | Q46595207 | ||
| The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel | Q46825496 | ||
| Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression | Q46868532 | ||
| MEK1 and MEK2 regulate distinct functions by sorting ERK2 to different intracellular compartments | Q46956856 | ||
| Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition | Q50335943 | ||
| Oncogenes and tumor suppressor genes. | Q53472800 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | targeted therapy | Q492646 |
| P304 | page(s) | 209-220 | |
| P577 | publication date | 2011-02-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
| P1476 | title | Novel mitogen-activated protein kinase kinase inhibitors | |
| P478 | volume | 20 |
| Q36351612 | Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants. |
| Q35041937 | BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors |
| Q39365692 | Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor |
| Q26752774 | Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature |
| Q38164679 | Dabrafenib therapy for advanced melanoma |
| Q34482125 | ERK1/2 and p38 MAPKs are complementarily involved in estradiol 17ß-D-glucuronide-induced cholestasis: crosstalk with cPKC and PI3K. |
| Q38083979 | Effect of inhibition of the FGFR–MAPK signaling pathway on the development of ocular toxicities |
| Q36582547 | Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma |
| Q36985669 | Inhibition of extracellular signal-regulated kinase 1/2 signaling has beneficial effects on skeletal muscle in a mouse model of Emery-Dreifuss muscular dystrophy caused by lamin A/C gene mutation |
| Q38982765 | Inhibition of tumor growth by U0126 is associated with induction of interferon-γ production |
| Q28534949 | Integrative modelling of the influence of MAPK network on cancer cell fate decision |
| Q34971882 | Interplay Between HGF/SF-Met-Ras Signaling, Tumor Metabolism and Blood Flow as a Potential Target for Breast Cancer Therapy |
| Q36253975 | MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia |
| Q36764687 | MEK1 is required for PTEN membrane recruitment, AKT regulation, and the maintenance of peripheral tolerance |
| Q26795510 | Managing Side Effects of Vemurafenib Therapy for Advanced Melanoma |
| Q27685364 | Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers |
| Q36301783 | Mitogen-activated protein kinase phosphatase (MKP)-1 in immunology, physiology, and disease |
| Q51287971 | Mitogen-activated protein kinases are involved in hepatocanalicular dysfunction and cholestasis induced by oxidative stress |
| Q35911350 | Personalized therapy in endometrial cancer: Challenges and opportunities |
| Q36086845 | Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer |
| Q36731185 | Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know |
| Q38791244 | Resolution of inflammation: a new therapeutic frontier |
| Q40072841 | Signature of microsatellite instability, KRAS and BRAF gene mutations in German patients with locally advanced rectal adenocarcinoma before and after neoadjuvant 5-FU radiochemotherapy |
Search more.